Luther
Looks to me like the NILVAD results will be significantly better than the drugs now being used to treat early Alzheimer’s. That alone should guarantee a very significant demand for nilvadipine when Archer gets approval to sell it as a treatment for Alzheimer’s.
My hope is that Roskamp will resist the temptation to keep the whole hog, but rather will license it out to one or more large Pharmas in exchange for license fees and generous royalties, leaving Archer free to focus on a 2nd generation AD drug.
My outlook about the whole Roskamp, Archer, Rock Creek situation is colored by the fact that when the RC shares outstanding were ballooning and the stock price plummeting, I loaded up to where my average cost basis is now under 9 cents, so I hunger for a big win here. Should nilvadipine turn out to be a financial success as I expect, then there will be plenty of money to bail out RC and combine with Archer on equal footing, becoming Archer Rock Creek Pharmaceutical, or ARC Pharma for short, with the symbol ARCP.
Anatabine’s success story can begin with a fairly quick, not too expensive Phase 3 study to prove anatabine’s anti-inflammatory mechanism of action, and the rest will be history!
The big question is will we current holders of Rock Creek shares be a part of this amazing story? Here too, given that Jonnie Williams, Robert Roskamp, and Dr. Michael Mullan are fellow shareholders, we are all in this same boat together.
Anyone else want to get in on this?
